POPULARITY
20 episodes with afatinib
26 episodes with afatinib
8 episodes with afatinib
Welcome to the Oncology Brothers podcast! In this episode, hosts Drs. Rahul and Rohit Gosain are joined by Dr. Gilberto Lopes, a thoracic medical oncologist from the Sylvester Cancer Center. Together, they dived into the latest updates on anti-EGFR drugs used in non-small cell lung cancer (NSCLC) with EGFR mutations. In this informative discussion, they covered: • The evolution of EGFR inhibitors, including Afatinib, Osimertinib, Amivantamab, and Lazertinib. • Common side effects associated with these treatments, such as diarrhea, skin toxicity, and infusion-related reactions. • Strategies for managing these side effects to improve patient quality of life and treatment adherence. • Insights from recent studies, including the SKIPirr trial and the MARIPOSA study, highlighting the benefits of new combinations and treatment approaches. Youtube: https://youtu.be/v6fb6nx0YY4 Follow us on social media: • X/Twitter: https://twitter.com/oncbrothers • Instagram: https://www.instagram.com/oncbrothers • Website: https://oncbrothers.com/ Join us as we explore how proactive management of side effects can maximize the effectiveness of these therapies and enhance patient outcomes. Don't forget to check out our other ToxCheck discussions, treatment algorithms, and conference highlights!
The OncoAlertWeekly Round Up Covering the TOP of the week April 18-24, 2025 REGISTER at http://OncoAlert360.com OR https://oncoalert.m-pages.com/nhMpwe/oncoalert-newsletter-registration Discussing:UPDATE on DESTINY-Breast09https://astrazeneca.com/media-centre/press-releases/2025/enhertu-combination-improved-pfs-in-1l-her-positive-mbc.htmlUPDATE on ASCENT 04https://gilead.com/news/news-details/2025/trodelvy-plus-keytruda-demonstrates-a-statistically-significant-and-clinically-meaningful-improvement-in-progression-free-survival-in-patients-with-previously-untreated-pd-l1-metastatic-tripAnnual Report to the Nationon the Status of Cancer, featuring state-level statistics after the onset of the COVID-19 pandemichttps://acsjournals.onlinelibrary.wiley.com/doi/full/10.1002/cncr.35833Osimertinib vs. Afatinib in 1L therapy of atypical EGFR-mutated metastatic non-small cell lung cancer https://lungcancerjournal.info/article/S0169-5002(25)00443-X/fulltextTargeting Lung Cancer with Precision: The ADC Therapeutic Revolutionhttps://link.springer.com/article/10.1007/s11912-025-01655-5Prevalence by therapy line and incidence of breast cancer brain metastases in 18 075 patientshttps://academic.oup.com/jnci/advance-article-abstract/doi/10.1093/jnci/djaf048/8101485?login=falseEuropean screening platform for EORTC clinical trials in advanced colorectal cancer ‘SPECTAcolor'https://esmogastro.org/article/S2949-8198(25)00037-8/fulltextKorea, Japan, Europe, and the United States: Why are guidelines for gastric cancer different?https://link.springer.com/article/10.1007/s10120-025-01613-xOutpatient Administration of Chimeric Antigen Receptor T-Cell Therapy Using Remote Patient Monitoringhttps://ascopubs.org/doi/10.1200/OP-25-00062Safety and Activity of Fibroblast Growth Factor Receptor Inhibitors in Advanced Malignancieshttps://ascopubs.org/doi/10.1200/PO-24-00896?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed
The preferred first-line treatment for patients with uncommon sensitizing mutations in tumor epidermal growth factor receptor (EGFR) should now be the tyrosine kinase inhibitor (TKI) afatinib, rather than osimertinib, according to Japanese researchers reporting the ACHILLES trial results at the ESMO Congress 2023 held in Madrid. OncTimesTalk correspondent Peter Goodwin talked with Satoru Miura, MD, from the Niigata Cancer Center Hospital in Japan, after he reported his findings at the ESMO meeting.
In this episode, Enriqueta Felip, MD, PhD, and Matthew Gubens, MD, MS, discuss evolving practice standards for EGFR-mutated non-small-cell lung cancer with topics including:Biomarker testing and strategiesOptimal first-line therapy in patients with NSCLCManagement of patients with CNS diseaseSelecting therapy for patients with noncanonical mutationsManagement strategies after progression on first-line EGFR TKI therapySelecting therapy for patients with early stage diseasePresenters: Enriqueta Felip, MD, PhDHead, Thoracic Oncology UnitOncology ServiceVall d'Hebron University HospitalBarcelona, SpainMatthew Gubens, MD, MSAssociate ProfessorThoracic OncologyUniversity of California, San FranciscoSan Francisco, CaliforniaContent based on an online CME program supported by an educational grant from AstraZeneca.Link to full program, including associated downloadable slidesets:https://bit.ly/2PpFFHM
Featuring perspectives from Dr Shirish M Gadgeel on the later-line management of metastatic squamous cell carcinoma of the lung. Recent advances in the management of advanced non-small cell lung cancer (NSCLC) (0:00) Case: A woman in her early 70s with metastatic squamous cell carcinoma (SCC) of the lung receives carboplatin/paclitaxel and pembrolizumab as first-line therapy on the KEYNOTE-021 trial (02:25) Response to pembrolizumab and chemotherapy in advanced SCC of the lung (04:34) Efficacy of pembrolizumab alone or in combination with chemotherapy for advanced NSCLC (07:41) Choice of immune checkpoint inhibitor/chemotherapy regimen as first-line therapy for metastatic SCC of the lung (12:22) Results of the Phase III CheckMate 227 trial evaluating nivolumab alone, with ipilimumab or with chemotherapy as first-line therapy for metastatic NSCLC (15:43) Interim overall survival analysis of the Phase III IMpower110 study investigating atezolizumab versus platinum-based chemotherapy for metastatic NSCLC in the first-line setting (18:32) Cancer site and adverse events induced by immune checkpoint inhibitors (20:05) Genetic alterations in patients with SCC of the lung; rationale for targeting the ERBB signaling pathway (22:18) Results of the Phase III LUX-Lung 8 trial of afatinib versus erlotinib as second-line treatment for advanced SCC of the lung (25:53) Secondary analysis of LUX-Lung 8: Association of ERBB mutations with clinical outcomes among patients with afatinib- or erlotinib-treated SCC of the lung (28:04) Role of HER2 mutations and HER2 amplification in patients with NSCLC; incidence of HER2 alterations in patients with SCC of the lung (30:14) Targeting HER2 alterations with the tyrosine kinase inhibitors afatinib and dacomitinib in patients with NSCLC (34:15) Efficacy of the antibody-drug conjugate trastuzumab deruxtecan (DS-8201) in patients with NSCLC and HER2 alterations (36:11) Activity of T-DM1 in patients with NSCLC and HER2 mutations (38:04) Management of gastrointestinal side effects associated with afatinib (40:22) Activity of afatinib in heavily pretreated ERBB2 mutation-positive advanced NSCLC (43:01) Afatinib in patients with metastatic or recurrent lung cancer with HER2 mutations (45:15) Case: A man in his early 80s develops metastases to the liver during treatment with durvalumab after chemoradiation therapy for Stage III SCC of the lung and is found to have FGFR1 amplification (47:15) FGFR signaling as a target for NSCLC therapy; outcomes with the FGFR inhibitor AZD4547 in patients with metastatic SCC of the lung and FGFR alterations (51:04) SWOG-S1400 Lung Cancer Master Protocol (Lung-MAP) — Biomarker-targeted therapy for patients with previously treated Stage IV SCC of the lung (56:02) Case: A woman in her early 50s with ALK-rearranged metastatic lung adenocarcinoma experiences a dramatic response to crizotinib on the PROFILE 1014 study (1:02:39) Response to ALK inhibitors for ALK-rearranged metastatic NSCLC (1:06:54) CME information and select publications
Dr. Nathan Pennell, Cleveland Clinic, describes treatment of NSCLC patients with HER2 mutations using agents such as Gilotrif or Herceptin.
Dr. Nathan Pennell, Cleveland Clinic, describes treatment of NSCLC patients with HER2 mutations using agents such as Gilotrif or Herceptin.
Dr. Nathan Pennell, Cleveland Clinic, describes treatment of NSCLC patients with HER2 mutations using agents such as Gilotrif or Herceptin.
Dr. Nathan Pennell, Cleveland Clinic, describes other options for treatment of acquired resistance, including chemotherapy, ablation with SBRT and a combination of Gilotrif and Erbitux.
Dr. Nathan Pennell, Cleveland Clinic, describes other options for treatment of acquired resistance, including chemotherapy, ablation with SBRT and a combination of Gilotrif and Erbitux.
Dr. Nathan Pennell, Cleveland Clinic, describes other options for treatment of acquired resistance, including chemotherapy, ablation with SBRT and a combination of Gilotrif and Erbitux.
Drs. Jack West and Greg Riely field questions about which treatments should EGFR lung cancer patients consider when their cancers progress.
Drs. Jack West and Greg Riely field questions about which treatments should EGFR lung cancer patients consider when their cancers progress.
Drs. Jack West and Greg Riely field questions about which treatments should EGFR lung cancer patients consider when their cancers progress.
Dr. Jack West suggests that progression in T790M-negative EGFR lung cancer patients may not require a change in therapy. In this video he details what should go into the decision to modify treatment for those patients.
Dr. Jack West suggests that progression in T790M-negative EGFR lung cancer patients may not require a change in therapy. In this video he details what should go into the decision to modify treatment for those patients.
Dr. Jack West suggests that progression in T790M-negative EGFR lung cancer patients may not require a change in therapy. In this video he details what should go into the decision to modify treatment for those patients.
Drs. Leora Horn, Ben Solomon, & Jack West discuss the open question of whether there are clinically significant differences among leading EGFR tyrosine kinases based on the specific EGFR mutation to be treated.
Drs. Leora Horn, Ben Solomon, & Jack West discuss the open question of whether there are clinically significant differences among leading EGFR tyrosine kinases based on the specific EGFR mutation to be treated.
Drs. Leora Horn, Ben Solomon, & Jack West discuss the open question of whether there are clinically significant differences among leading EGFR tyrosine kinases based on the specific EGFR mutation to be treated.
MSKCC medical oncologist Dr. Greg Riely reviews the optimal first line treatment of patients with an EGFR mutation-positive advanced lung cancer.
MSKCC medical oncologist Dr. Greg Riely reviews the optimal first line treatment of patients with an EGFR mutation-positive advanced lung cancer.
MSKCC medical oncologist Dr. Greg Riely reviews the optimal first line treatment of patients with an EGFR mutation-positive advanced lung cancer.
Medical oncologist Dr. Greg Riely, MSKCC, summarizes the development of acquired resistance after a good initial response to EGFR inhibitor therapy and the clinical patterns of progression commonly seen.
Medical oncologist Dr. Greg Riely, MSKCC, summarizes the development of acquired resistance after a good initial response to EGFR inhibitor therapy and the clinical patterns of progression commonly seen.
Medical oncologist Dr. Greg Riely, MSKCC, summarizes the development of acquired resistance after a good initial response to EGFR inhibitor therapy and the clinical patterns of progression commonly seen.
Dr. Greg Riely, medical oncologist from MSKCC, considers the evidence on whether there are clinically significant differences among the currently available first and second generation oral EGFR inhibitors for patients with an EGFR mutation.
Dr. Greg Riely, medical oncologist from MSKCC, considers the evidence on whether there are clinically significant differences among the currently available first and second generation oral EGFR inhibitors for patients with an EGFR mutation.
Dr. Greg Riely, medical oncologist from MSKCC, considers the evidence on whether there are clinically significant differences among the currently available first and second generation oral EGFR inhibitors for patients with an EGFR mutation.
Medical oncologist Dr. Greg Riely, MSKCC, discusses evidence for whether there are clinically significant differences among specific EGFR mutations that should lead to differences in management.
Medical oncologist Dr. Greg Riely, MSKCC, discusses evidence for whether there are clinically significant differences among specific EGFR mutations that should lead to differences in management.
Medical oncologist Dr. Greg Riely, MSKCC, discusses evidence for whether there are clinically significant differences among specific EGFR mutations that should lead to differences in management.
Dr. Jack West, medical oncologist, reviews evidence in favor of adding Avastin (bevacizumab) to the EGFR inhibitor Tarceva (erlotinib) for patients with lung cancer that harbors an activating EGFR mutation.
Dr. Jack West, medical oncologist, reviews evidence in favor of adding Avastin (bevacizumab) to the EGFR inhibitor Tarceva (erlotinib) for patients with lung cancer that harbors an activating EGFR mutation.
Dr. Jack West, medical oncologist, reviews evidence in favor of adding Avastin (bevacizumab) to the EGFR inhibitor Tarceva (erlotinib) for patients with lung cancer that harbors an activating EGFR mutation.
Squamous cell carcinoma patients have limited options. Data presented at ASCO 2015 showed positive patient outcomes with Gilotrif (afatinib) vs Tarceva (erlotinib), but some feel that there is little value in a treatment with only modestly better results.
Squamous cell carcinoma patients have limited options. Data presented at ASCO 2015 showed positive patient outcomes with Gilotrif (afatinib) vs Tarceva (erlotinib), but some feel that there is little value in a treatment with only modestly better results.
Squamous cell carcinoma patients have limited options. Data presented at ASCO 2015 showed positive patient outcomes with Gilotrif (afatinib) vs Tarceva (erlotinib), but some feel that there is little value in a treatment with only modestly better results.
Dr Jean-Pascal Machiels of Cliniques Universitaires Saint-Luc, Brussels, Belgium talks to ecancertv at ESMO 2014 in Madrid Spain. He presents results from a phase III trial on the tyrosine kinase inhibitor, afatinib and the significant improvements it has shown in progression-free survival for patients with recurrent or metastatic squamous cell carcinoma of the head and neck after failure of platinum-based chemotherapy. Afatinib is a compound that irreversibly blocks the ErbB family of cell surface receptors, which includes epidermal growth factor receptor (EGFR), human epidermal growth factor receptor 2 (HER2), HER3 and HER4.
Acquired Resistance Forum Video #15: Dr. Pasi Jänne of Dana-Farber Cancer Institute spoke about EGFR inhibitors available to patients when Tarceva stops working for them.
Acquired Resistance Forum Video #15: Dr. Pasi Jänne of Dana-Farber Cancer Institute spoke about EGFR inhibitors available to patients when Tarceva stops working for them.
Acquired Resistance Forum Video #15: Dr. Pasi Jänne of Dana-Farber Cancer Institute spoke about EGFR inhibitors available to patients when Tarceva stops working for them.
HER2 inhibitors have been successfully used to combat breast cancer, but research has shown that a small percentage of lung cancer patients have a HER2 mutation as well. Dr. Leena Gandhi talks about the role that HER2 drugs may play to fight lung cancer.
HER2 inhibitors have been successfully used to combat breast cancer, but research has shown that a small percentage of lung cancer patients have a HER2 mutation as well. Dr. Leena Gandhi talks about the role that HER2 drugs may play to fight lung cancer.
HER2 inhibitors have been successfully used to combat breast cancer, but research has shown that a small percentage of lung cancer patients have a HER2 mutation as well. Dr. Leena Gandhi talks about the role that HER2 drugs may play to fight lung cancer.
An analysis of two large studies of EGFR lung cancer patients tried to determine if Gilotrif helped patients live longer.
An analysis of two large studies of EGFR lung cancer patients tried to determine if Gilotrif helped patients live longer.
An analysis of two large studies of EGFR lung cancer patients tried to determine if Gilotrif helped patients live longer.
Dr. Geoffrey Oxnard of Dana-Farber Cancer Institute describes what research indicates may be more successful treatments for EGFR lung cancer patients.
Dr. Geoffrey Oxnard of Dana-Farber Cancer Institute describes what research indicates may be more successful treatments for EGFR lung cancer patients.
Dr. Geoffrey Oxnard of Dana-Farber Cancer Institute describes what research indicates may be more successful treatments for EGFR lung cancer patients.
Dr. Phil Bonomi, from Rush University, describes the generations of EGFR inhibitors beginning with Gefitinib (Iressa).
Dr. Phil Bonomi, from Rush University, describes the generations of EGFR inhibitors beginning with Gefitinib (Iressa).
Dr. Phil Bonomi, from Rush University, describes the generations of EGFR inhibitors beginning with Gefitinib (Iressa).
Dr. Natasha Leighl, Princess Margaret Hospital in Toronto, Canada, reviews new data supporting new treatment options for EGFR mutation-positive patients with advanced NSCLC being newly treated or developing acquired resistance to prior EGFR inhibitors.
Dr. Natasha Leighl, Princess Margaret Hospital in Toronto, Canada, reviews new data supporting new treatment options for EGFR mutation-positive patients with advanced NSCLC being newly treated or developing acquired resistance to prior EGFR inhibitors.
Dr. Natasha Leighl, Princess Margaret Hospital in Toronto, Canada, reviews new data supporting new treatment options for EGFR mutation-positive patients with advanced NSCLC being newly treated or developing acquired resistance to prior EGFR inhibitors.
Dr. Natasha Leighl, Princess Margaret Hospital in Toronto, Canada, reviews new data supporting new treatment options for EGFR mutation-positive patients with advanced NSCLC being newly treated or developing acquired resistance to prior EGFR inhibitors.
Dr. Natasha Leighl, Princess Margaret Hospital in Toronto, Canada, reviews new data supporting new treatment options for EGFR mutation-positive patients with advanced NSCLC being newly treated or developing acquired resistance to prior EGFR inhibitors.
Dr. Natasha Leighl, Princess Margaret Hospital in Toronto, Canada, reviews new data supporting new treatment options for EGFR mutation-positive patients with advanced NSCLC being newly treated or developing acquired resistance to prior EGFR inhibitors.
Dr. David Spigel, Sarah Cannon Cancer Center, offers his perspective on the agents he feels most likely to become clinical tools against lung cancer over the next few years.
Dr. David Spigel, Sarah Cannon Cancer Center, offers his perspective on the agents he feels most likely to become clinical tools against lung cancer over the next few years.
Dr. David Spigel, Sarah Cannon Cancer Center, offers his perspective on the agents he feels most likely to become clinical tools against lung cancer over the next few years.
Drs. Mark Socinski from Univ. of Pittsburgh and Joel Neal from Stanford Cancer Center answer questions about topics covered in the summary of lung cancer highlights from ASCO 2012.
Drs. Mark Socinski from Univ. of Pittsburgh and Joel Neal from Stanford Cancer Center answer questions about topics covered in the summary of lung cancer highlights from ASCO 2012.
Dr. Joel Neal covers results with afatinib, an irreversible "pan-HER inhibitor", compared with standard chemo for patients with advanced NSCLC and an EGFR mutation.
Dr. Joel Neal covers results with afatinib, an irreversible "pan-HER inhibitor", compared with standard chemo for patients with advanced NSCLC and an EGFR mutation.
Q and A session with Dr. Jared Weiss, Medical Oncologist at UNC-Chapel Hill, about highlights in lung cancer in 2011.
Q and A session with Dr. Jared Weiss, Medical Oncologist at UNC-Chapel Hill, about highlights in lung cancer in 2011.
Dr. Jared Weiss, Medical Oncologist at UNC-Chapel Hill, reviews lung cancer highlights in 2011, focusing here on treatments focusing on the EGFR axis.
Dr. Jared Weiss, Medical Oncologist at UNC-Chapel Hill, reviews lung cancer highlights in 2011, focusing here on treatments focusing on the EGFR axis.
Case-based discussion with multiple lung cancer experts on optimal treatment of a patient with advanced lung adenocarcinoma, EGFR mutation, & now acquired resistance to EGFR TKI after very good prior response.
Case-based discussion with multiple lung cancer experts on optimal treatment of a patient with advanced lung adenocarcinoma, EGFR mutation, & now acquired resistance to EGFR TKI after very good prior response.
Question and answer session with Drs. Mary Pinder-Schenck from Moffitt Cancer Center in Tampa and Nasser Hanna from Indiana University about highlights in lung cancer from ASCO 2011 annual meeting.
Question and answer session with Drs. Mary Pinder-Schenck from Moffitt Cancer Center in Tampa and Nasser Hanna from Indiana University about highlights in lung cancer from ASCO 2011 annual meeting.
Dr. Nasser Hanna from Indiana University Cancer Center reviews highlights of presentations on advanced/metastatic NSCLC from the ASCO 2011 annual meeting.
Dr. Nasser Hanna from Indiana University Cancer Center reviews highlights of presentations on advanced/metastatic NSCLC from the ASCO 2011 annual meeting.
© 2020-2025 Ivy Podcast Discovery LLC
